MDT
FY2026 Q4 · Calendar Q2 2026
Medtronic plc
Medtronic closed fiscal 2026 with its strongest top-line performance in a decade — $9.8B in Q4 revenue, up 9.9% YoY, and $36.4B for the full year. Cardiac Ablation Solutions (CAS) crossed $2B annualized with 78% global growth, solidifying it as the company's lead growth engine. The MiniMed diabetes business completed its IPO spin-off, streamlining the portfolio toward higher-margin platforms. Management raised FY27 guidance to 6.75–7.25% organic revenue growth and EPS of $5.90–$6.00, stepping up from the prior quarter's qualitative 'high-single-digit EPS growth' framing. The diversified growth platform — CAS, Symplicity renal denervation, Hugo surgical robotics, Altaviva, and Stealth AXiS — is delivering, though tariff exposure has grown and TAVR remains a soft spot.
EPS surprise+0.6%
Market move+5.7%
